BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa...

Published on 19 Nov 2024 on Benzinga · via Yahoo Finance

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM...

Read the rest of the article

Start tracking your investments with Statfolio

The approval came ahead of the targeted action date of Nov. 29. Per... Plunges on Study Failure...

Zacks · via Yahoo Finance 29 Nov 2024

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults wit...

Zacks · via Yahoo Finance 26 Nov 2024

BridgeBio Pharma, Inc. (NASDAQ:BBIO) received U.S. Food and Drug Administration (FDA) approval fo...

Investing.com 25 Nov 2024

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...

Investing.com 25 Nov 2024

(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulator...

Bloomberg · via Yahoo Finance 25 Nov 2024

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an...

Benzinga · via Yahoo Finance 25 Nov 2024

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

PALO ALTO, CA—Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc....

Investing.com 20 Nov 2024

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM...

Benzinga · via Yahoo Finance 19 Nov 2024

One thing we could say about the analysts on BridgeBio Pharma, Inc. (NASDAQ:BBIO) - they aren't...

Simply Wall St. · via Yahoo Finance 18 Nov 2024